The Discounted Cash Flow (DCF) valuation of Akebia Therapeutics Inc (AKBA) is (3.80) USD. With the latest stock price at 2.55 USD, the upside of Akebia Therapeutics Inc based on DCF is -249.1%.
Based on the latest price of 2.55 USD and our DCF valuation, Akebia Therapeutics Inc (AKBA) is a sell. selling AKBA stocks now will result in a potential gain of 249.1%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.9% - 8.1% | 7.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (12.35) - (2.31) | (3.80) |
| Upside | -584.4% - -190.6% | -249.1% |